Skip to main content
Fig. 3 | Journal of Experimental & Clinical Cancer Research

Fig. 3

From: Targeted inhibition of PDGFRA with avapritinib, markedly enhances lenvatinib efficacy in hepatocellular carcinoma in vitro and in vivo: clinical implications

Fig. 3

PDGFRA inhibitor avapritinib sensitizes HCC cells to lenvatinib treatment. (A) The effect of lenvatinib and avapritinib was tested in the colony-formation assay in SMMC-7721-LR and SNU-449-LR cells. (B) Synergistic response to the combination of lenvatinib and avapritinib in PDGFRA high C3A and SNU-398 cells and in PDGFRA low SMMC-7721 and SNU-449 cells. (C) Representative tumor images of each group of SMMC-7721-LR xenografts at the end of lenvatinib, avapritinib or combination treatment. (D) Tumor growth curves and tumor weight of each group are shown. (E) Representative H&E staining, IHC images of PDGFRA and Ki67 in subcutaneous implantation mouse model. (F) Representative tumor images of each group of PDGFRA overexpressing SMMC-7721 xenografts at the end of lenvatinib, avapritinib or combination treatment. (G) Tumor growth curve and tumor weight of each group (H) Representative H&E staining, IHC images of PDGFRA and Ki67 in subcutaneous implantation mouse model

Back to article page

Journal of Experimental & Clinical Cancer Research

ISSN: 1756-9966

Contact us